Navigation Links
Lexicon Completes Phase 2 Study Of LX1033 In IBS-d
Date:12/3/2013

THE WOODLANDS, Texas, Dec. 3, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

The primary endpoint of this study was the change in stool consistency averaged from baseline to day 28. All treatment groups, including placebo, showed significant improvements over time, yet differences between placebo and LX1033 in stool consistency were not statistically significant. Further analyses of the stool consistency data were performed adjusting for early terminations which may have enhanced the placebo response rate. These additional analyses of stool consistency yielded favorable results for the LX1033 500mg three times daily dose group compared to placebo, and some of these findings were associated with statistically significant results (p<0.05). LX1033 reduced the production of plasma 5-HIAA (a biomarker for serotonin synthesis) significantly more than placebo, with the greatest reductions observed in the 500 mg three times daily dose group. This same LX1033 dose also produced the greatest reduction in abdominal pain, an important measure of efficacy in IBS-d. The proportion of patients showing an abdominal pain intensity weekly response (defined as a reduction in abdominal pain of at least 30% from baseline for at least 50% of the weeks assessed, with no worsening from baseline in stool consistency) was 33% on placebo and 47% on LX1033 500 mg given three times daily (p<0.05). LX1033 was safe and well tolerated in the study, with adverse events evenly distributed among LX1033 trea
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
(Date:10/22/2014)... -- InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based in ... cord injury (SCI) treatment with their novel Neuro-Spinal Scaffold. ... regrowth in the spinal cord area when cells are ... polymer, the scaffold ultimately breaks down to water and ... NVIV has recently attracted significant investor attention with the ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... Spinal Cord,Injury Model With ZFP TF Treatment, RICHMOND, ... announced today the presentation of preclinical,data from its ... Annual Conference of the American Society for Neural,Therapy ... of spinal cord,injury (SCI), demonstrate that treatment of ...
... 2007 /PRNewswire-FirstCall/ --,Citing issues related to potentially ... has concluded that the COSTAR,II (CObalt Chromium ... study for the CoStar cobalt chromium,paclitaxel-eluting coronary ... trial did not identify safety issues, and ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 2Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 3Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 4Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 2Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 3Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 4
(Date:10/25/2014)... (HealthDay News) -- Interrupting blood supply to an arm or ... associated with the surgery, according to a new study. ... supply to the heart to be able to operate on ... reduce its ability to produce energy because it doesn,t get ... large muscle, such as an arm or a leg, the ...
(Date:10/25/2014)... THURSDAY, Oct. 23, 2014 (HealthDay News) -- A large ... West Africa is to avoid tens of thousands of ... Yale University researchers predict. Using a specially ... future of the outbreak in just one densely populated ... the capital city of Monrovia. The researchers said ...
(Date:10/22/2014)... Pennsylvania (PRWEB) October 22, 2014 At ... and uncertainty among parents and athletes at all levels, ... working to change the current discussion where two powerful ... are evidence-based therapies that result in full recoveries every ... to one based in fact and research, UPMC and ...
(Date:10/22/2014)... MI (PRWEB) October 22, 2014 ... Schools of Allied Health Professions (ASAHP) Conference on October ... and CEO will participate in a panel discussion on ... Practice. , Isabel Healthcare provides a diagnostic decision support ... improving the diagnosis skills of students and clinical learners. ...
(Date:10/22/2014)... 2014 Shriners Hospitals for Children® and ... the current location of Shriners Hospitals for Children - ... from the University of Kentucky Albert B. Chandler Hospital. ... center, owned and operated by Shriners Hospitals for Children, ... children and their families well into the future. , ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3
... centres will soon need to be registered and also adhere ... a new draft ‘Clinical Establishment Bill’ that has been finalised ... cabinet for approval. ,The proposed law will apply ... or Ayurvedic and the same parameters will apply to a ...
... scientists have successfully grown large numbers of stem cells taken ... to repair some of the tissue// damage done to those ... in humans, making them a useful model in such research. ... a thin tube to extract samples of heart tissue no ...
... proposes to link-up with tour operators to design tour ... and recreation in// the itinerary of tourists. ... secretary for Sports and Wellness of the Department of ... (Philippine Travel Agencies Association) and Naitas (The National Association ...
... Pharmaceutical Technology, Jadavpur University, Kolkata and Department of ... a// study on Plumeria Acuminata leaves. The objective ... anti-inflammatory activity of methanol extract of leaves of ... inflammation in rat hind paw oedema models. ...
... Science Award from Keio University in Tokyo. Mr. Steitz, ... received the award in a ceremony and commemorative symposium conducted ... award, made to researchers in recognition of their outstanding achievements ... only prize of its kind awarded by a Japanese University. ...
... who react slowly and possess bad memories are more prone ... ,Dr.Beverly Shipley, aged 28, from the Psychology dept., Edinburgh University ... heart attacks may be linked. She surveyed the mental agility ... all over Britain. ,She says that those with ...
Cached Medicine News:Health News:Pig Stem Cells Show Promise in Repairing Animals’ Heart Attack Damag 2Health News:Pig Stem Cells Show Promise in Repairing Animals’ Heart Attack Damag 3Health News:Anti Inflammatory Evaluation Of Plumeria Acuminata Leaves 2Health News:Yale Scientist Received Medical Science Prize From Keio University 2
... 2 O W/O Adapter., ... humidifier systems feature a dual-purpose reservoir with a ... secure attachment of a humidifier adapter. The oxygen ... reaching oxygen delivery tubing. An audible relief valve ...
... EMPTY W/AIR ENT 35%-100% FIO2, ,Empty ... 35% to 100%. It has ports for ... ,Empty Nebulizers 5007P and 5207 have ... , ,Convenient slip-on heaters are also ...
... , One device provides ... therapy from a single gas source ... decreasing the number of SKUs dedicated ... and inconvenience of double or wye ...
MISTY OX® Hi-Fi Nebulizer...
Medicine Products: